NEUMORA THERAPEUTICS
14.74
08-October-24 15:59:59
15 minutes delayed
Stocks
+0.18
+1.24%
Today's range
14.27 - 15.00
ISIN
N/A
Source
NASDAQ
-
14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire
-
20 Jun 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
14 May 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07 May 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics to Participate in Upcoming Conferences in May
06 May 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
15 Apr 2024 06:30:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics to Participate in Upcoming Conferences in November
30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire
-
10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire
-
Neumora Therapeutics Announces Pricing of Initial Public Offering
14 Sep 2023 20:49:04 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >